RxDoctor Payments Data

Nancy Anderson, MD

Dermatology · Loma Linda, CANPI 1710091806

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $269,483 of the $300,150 with a category attached, or 89.8%. 19 manufacturers reported payments, led by AbbVie at 40.7% of the total. Reporting peaked in 2019 at $78,326 and has fallen 60.8% since, to $30,679 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$300,150in general payments, 2019–2025

Across 329 payments — averaging $912.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$122K
  • Amgen$103K
  • Pfizer$24K
  • Sanofi$17K
  • Novartis$13K
  • Bristol Myers Squibb$9K
  • plus $12K from 13 others
$33,896in research payments, 2019–2025

Across 44 payments — averaging $770.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$25K
  • Janssen Research & Development, LLC$9K

What the payments were for

  • Consulting fees$1,7951%
  • Speaking & faculty fees$269,48390%
  • Travel & lodging$19,8317%
  • Food & beverage$8,9963%
  • Education$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$300,150 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California →

Medicare billing

Part B allowed, 2024
$162,068
Medicare patients
278
Services billed
2,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5045$749,832
Humira(Cf) PenAdalimumab20$459,175
Skyrizi PenRisankizumab-Rzaa21$427,511
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5020$307,018
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5021$217,660
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$136,797
Ketoconazole229$4,025
Metronidazole34$2,860
Mycophenolate Mofetil53$2,734
Clobetasol Propionate43$2,691
Fluorouracil37$2,445
Tacrolimus12$1,599
Triamcinolone Acetonide82$1,331
Doxycycline Hyclate18$973
Fluocinonide16$892

Paid to pharmacies, not to this prescriber.

Other dermatology in Loma Linda

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →